Emerging pathways as individualized therapeutic target of multiple myeloma

A critical role for the NFkB pathway in multiple myeloma

(2015)   Oncotarget

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma

(2015) Nicola Amodio et al.   Oncotarget

In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma

(2015) Maria Teresa Di Martino et al.   Oncotarget

Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth

(2013) E. Leone et al.   CLINICAL CANCER RESEARCH

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)

(2012) Tianhong Li et al.   BREAST CANCER RESEARCH AND TREATMENT

Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

(2012) M. T. Di Martino et al.   CLINICAL CANCER RESEARCH

Molecular Targets for the Treatment of Multiple Myeloma

(2012) Marco Rossi et al.   CURRENT CANCER DRUG TARGETS

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma

(2012) P. Tagliaferri et al.   CURRENT CANCER DRUG TARGETS

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma

(2012) P. Tassone et al.   CURRENT CANCER DRUG TARGETS

Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity

(2012) Paul G Richardson et al.   Expert Opinion on Drug Metabolism & Toxicology

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype

(2012) C Stengel et al.   LEUKEMIA

Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway

(2012) Vijay Ramakrishnan et al.   PLoS One

The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies

(2012) Philippe Moreau   SEMINARS IN HEMATOLOGY

miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

(2012) N Amodio et al.   Cell Death & Disease

Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma

(2011) Philipp Baumann et al.   ANTI-CANCER DRUGS

Epigenetic inactivation of the MIR34B/C in multiple myeloma

(2011) K. Y. Wong et al.   BLOOD

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

(2011) G. J. Morgan et al.   BLOOD

Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma

(2011) Sally A. Hunsucker et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors

(2011) H. R. Hudlebusch et al.   CLINICAL CANCER RESEARCH

Treatment Options for Relapsed and Refractory Multiple Myeloma

(2011) Sagar Lonial et al.   CLINICAL CANCER RESEARCH

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

(2011) Irene M Ghobrial et al.   LANCET ONCOLOGY

A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells

(2011) T Calimeri et al.   LEUKEMIA

Animal models: Towards a myeloma mouse

(2011) Sarah DeWeerdt   NATURE

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Treatment of multiple myeloma

(2011) S. Vincent Rajkumar   Nature Reviews Clinical Oncology

Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies

(2010) N. Reddy et al.   ANNALS OF ONCOLOGY

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

(2010) T. Steinbrunn et al.   BLOOD

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

(2010) Kihyun Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development

(2010) Flavia Pichiorri et al.   CANCER CELL

Emerging therapies for the treatment of relapsed or refractory multiple myeloma

(2010) Meletios A. Dimopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Oligonucleotide delivery in cancer therapy

(2010) Giuseppe De Rosa et al.   Expert Opinion on Drug Delivery

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

(2010) L. Lode et al.   HAEMATOLOGICA

Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma

(2010) T. Rasmussen et al.   HAEMATOLOGICA

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

(2010) Gareth J Morgan et al.   LANCET

Combined Inhibition of Notch Signaling and Bcl-2/Bcl-xL Results in Synergistic Antimyeloma Effect

(2010) M. Li et al.   MOLECULAR CANCER THERAPEUTICS

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma

(2009) A. M. Roccaro et al.   BLOOD

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

(2009) D. W. McMillin et al.   CANCER RESEARCH

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

(2009) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects

(2009) M. Marra et al.   CURRENT CANCER DRUG TARGETS

Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy

(2009) P. Tassone et al.   CURRENT CANCER DRUG TARGETS

Zoledronic acid: an unending tale for an antiresorptive agent

(2009) Michele Caraglia et al.   EXPERT OPINION ON PHARMACOTHERAPY

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin

(2009) P. Frost et al.   MOLECULAR CANCER THERAPEUTICS

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

(2008) A. Zollinger et al.   BLOOD

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

(2008) Joseph R. Mikhael et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical and biological significance of RAS mutations in multiple myeloma

(2008) W J Chng et al.   LEUKEMIA

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

(2008) Ling Lu et al.   MICROVASCULAR RESEARCH

Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells

(2007) F Condorelli et al.   BRITISH JOURNAL OF PHARMACOLOGY